Reis REIS 深 沪
等待开盘 06-26 09:30:00 美东时间
22.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 22.99
- 总市值 2.66亿
- 52周最高 23.81
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 16.085
- 委 比 0.00%
- 总股本 1156.98万
- 历史最高 26.22
- 量 比 0
- 振 幅 0.00%
- 历史最低 5.03
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stantec President/CEO Johnston set to retire, succeeded by Reisbord
Stantec (STN) said late Wednesday that Gord Johnston will retire as President and CEO effective October 1 but will remain on the board as vice chair. Susan Reisbord, currently COO of the company's Nor...
06-18 21:21
Gord Johnston to Transition to Vice Chair of Stantec’s Board of Directors
Stantec announced that Gord Johnston will retire as CEO effective October 1, and Susan Reisbord, current COO of North America, will succeed him. This transition follows a Board-led succession plan, ensuring continuity in client relationships and operations. Reisbord, with over 30 years of industry experience, joined Stantec in 2021 via the Cardno acquisition. Johnston praised Reisbord's leadership and expressed confidence in the company's future ...
06-17 21:00
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Pasithea Therapeutics Corp. will participate in the Children's Tumor Foundation's 2026 NF Conference in Denver, Colorado, to engage with the NF1 community following FDA Fast Track and Rare Pediatric Disease Designations for its lead treatment candidate PAS-004. The company aims to develop safer, long-term therapies for NF1 patients and encourages participants to contact them in advance for meetings. PAS-004 is a next-generation macrocyclic MEK in...
06-15 11:02
Magnera Announces the Sale of Its Caerphilly, United Kingdom Operations
Magnera Corporation has sold its Caerphilly, UK operations, which produce metallized paper for premium labels, gift wrap, and food packaging, to Polyart Group, a Prudentia Capital holding. Magnera CEO Curt Begle thanked the Caerphilly team and emphasized commitment to a seamless transition for customers. Dominik Zwerger of Prudentia Capital expressed excitement about adding the operations to their portfolio and leveraging the management team's ex...
06-15 06:00
Caleres Q1 2026 Earnings Call Transcript
Caleres (NYSE:CAL) held its first-quarter earnings conference call on Thursday....
06-04 22:47
Origin Enterprises Reissues Treasury Shares to Satisfy Employee Options
The latest update is out from Origin Enterprises plc ( ($GB:OGN) ). Origin Ente...
06-03 22:05
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics Corp. announced that the FDA has granted Orphan Drug Designation to PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). ALS is a fatal neurodegenerative disease with limited treatment options. The designation provides benefits like tax credits, fee exemptions, and market exclusivity. Pasithea is currently testing PAS-004 in clinical trials for advanced cancer and neurofibromatosis type 1.
06-02 11:02
LIVE MARKETS-The hidden costs of the AI gold rush
LIVE MARKETS-The hidden costs of the AI gold rush S&P 500, Nasdaq both modestly higher, Dow slips Axios reported U.S. and Iran deal to extend ceasefire Euro STOXX 600 Index off ~0.4% Dollar falls; bitcoin down >3%; gold, US Crude up slightly US 10-year Treasury yield edges down to ~4.47% Welcome to
05-28 22:56
Transcript: Motorsport Games Q1 2026 Earnings Conference Call
Motorsport Games (NASDAQ:MSGM) reported first-quarter financial results on Wedn...
05-14 05:30
Pasithea Therapeutics appoints chief medical officer
Pasithea Therapeutics (KTTA) said on Monday it appointed Kartik Krishnan as chief medical officer as it advances its lead candidate, PAS-004, which is a next-generation MEK inhibitor Krishnan will ove...
05-04 20:34
